Zai Lab Ltd. logo

Zai Lab Ltd. (ZLAB)

Market Closed
15 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
35. 17
+0.89
+2.61%
$
3.88B Market Cap
- P/E Ratio
0% Div Yield
837,143 Volume
-3.45 Eps
$ 34.28
Previous Close
Day Range
34.58 35.23
Year Range
16.01 44.34
Want to track ZLAB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 22 days
Zai Lab Limited Is Well Positioned For Long-Term Growth

Zai Lab Limited Is Well Positioned For Long-Term Growth

Zai Lab leverages partnerships and regulatory expertise to commercialize innovative drugs in China, reducing trial risks and accelerating market entry. A robust pipeline with multiple anticipated product launches each year, driving strong revenue growth toward a $1.5–$2 billion target by 2028. The company's strong balance sheet and diverse product portfolio minimize risk.

Seekingalpha | 1 month ago
Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript

Zai Lab Limited (NASDAQ:ZLAB ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Jonathan Wang - Chief Business Officer Conference Call Participants Michael Yee - Jefferies Louise Chen - Scotiabank Yen-Der Li - Leerink Partners Li Watsek - Cantor Yigal Nochomovitz - Citi Anupam Rama - JPMorgan Jack Lin - Morgan Stanley Rebecca Liang - Bernstein Linhai Zhao - Goldman Sachs Operator Hello, ladies and gentlemen, thank you for standing by, and welcome to Zai Lab's First Quarter 2025 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Seekingalpha | 2 months ago
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 2 months ago
All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy

All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy

Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 3 months ago
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?

Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks | 3 months ago
Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth

Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth

Zai Lab Limited is an innovative Pharma partnering with US and European Pharmas to secure approvals for, and market their drugs in China. ZLAB stock has surged over 105% in the past year, driven by strong revenue growth and ambitious plans for future drug launches. The company aims to achieve $2bn in annual revenues by 2028, with key drugs like Vyvgart and Cobenfy leading the charge.

Seekingalpha | 3 months ago
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

ZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China.

Seekingalpha | 3 months ago
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet

Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet

The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 4 months ago
Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript

Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript

Zai Lab Limited (NASDAQ:ZLAB ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Head of Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Michael Yee - Jefferies Yen-Der Li - Leerink Partners Reena Patel - Citi Linhai Zhao - Goldman Sachs Li Wang Watsek - Cantor Fitzgerald Po Han Lin - Morgan Stanley Operator Hello, ladies and gentlemen. Thank you for standing by and welcome to Zai Lab's Fourth Quarter and Full Year 2024 Financial Results Conference Call.

Seekingalpha | 4 months ago
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?

Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?

Zai Lab Limited (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks | 4 months ago
Here's Why 'Trend' Investors Would Love Betting on Zai Lab Limited (ZLAB)

Here's Why 'Trend' Investors Would Love Betting on Zai Lab Limited (ZLAB)

Zai Lab Limited (ZLAB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks | 4 months ago
Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade

Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade

The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 5 months ago
Loading...
Load More